Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.80 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.80 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351863 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4085052 | 0.88 | PTGER4 (0.98) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Diethylamine SCHEMBL3019803 | 0.85 | PTGER4 (0.91) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL13655932 | 0.85 | PTGER4 (0.69) | PTGER4PTGER2 | |
| SCHEMBL2352729 | 0.82 | PTGER4 (1.00) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4100421 | 0.81 | PTGER4 (0.98) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL13210500 | 0.81 | PTGER4 (0.86) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4085048 | 0.80 | PTGER4 (0.83) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4090366 | 0.80 | PTGER4 (0.83) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL13230152 | 0.79 | PTGER4 (0.62) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | DAVIES IAN | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | PTGER4, P2RY4, PTGES2 | PTGER4 1/4885PTGER2 7/4885PTGDR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.